Humanigen   Report issue

For profit Phase 2 Phase 3
Founded: Brisbane CA United States (2001)

Organization Overview

First Clinical Trial
2008
NCT00638365
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Humanigen, Inc. | KaloBios Pharmaceuticals | KaloBios Pharmaceuticals, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Asthma (Phase 2)

Coronavirus Infections (Phase 3)

Cystic Fibrosis (Phase 2)

Fibrosis (Phase 2)

Glioblastoma (Phase 1)

Leukemia (Phase 1)

Leukemia, Myelomonocytic, Acute (Phase 1)

Leukemia, Myelomonocytic, Chronic (Phase 1)

Leukemia, Myelomonocytic, Juvenile (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 2)

Pneumonia (Phase 3)

Pneumonia, Ventilator-Associated (Phase 2)

Preleukemia (Phase 2)

Primary Myelofibrosis (Phase 2)

Pseudomonas Infections (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 7